Trial Profile
A Phase I/II Trial of SGN-00101 [verpasep caltespen] in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Verpasep caltespen (Primary)
- Indications Anal cancer; Anal intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 07 Oct 2005 New trial record.